top of page
  • Writer's pictureMichelle Pugle

FDA Approves Lodoco, First Anti-Inflammatory Drug for Cardiovascular Disease. Here's Why It's a Big Deal

July 2023: The Food and Drug Administration (FDA) has approved the first-ever anti-inflammatory drug for cardiovascular disease.

Called LODOCO (colchicine, 0.5mg), the recently approved medication has been shown to reduce cardiac event risk in adults with atherosclerotic cardiovascular disease (ASCVD) or with multiple risk factors for cardiovascular disease by an additional 31% compared to standard-of-care treatment. This means colchicine can be used in the prevention and treatment of cardiovascular disease.

The FDA-approval is supported by data from a multi-national, randomized, double-blind, placebo-controlled clinical trial including 5,522 people with chronic coronary disease taking guideline-directed medical care including high-intensity statins.

Read more in Healthline.


Michelle Pugle, MA

bottom of page